Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. What's spooking ...

AbbVie and its longtime blockbuster arthritis drug Humira are now front and center in the Outcome Health trial. Outcome Health was a high-flying Chicago company that made headlines when it raised $488 ...

Increased uptake of biosimilars on par with the utilization rates of filgrastim biosimilars could have saved Medicare Part D $84 million in 2019. Medicare Part D spending on biologics is growing and ...

Dublin, June 21, 2019 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. "Plaque Psoriasis: Global ...

Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year ...